4/9
12:09 pm
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
4/9
08:13 am
galt
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Medium
Report
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
4/9
08:00 am
galt
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Medium
Report
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
4/1
11:04 pm
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/1
01:04 pm
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
3/29
08:03 am
galt
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/29
08:00 am
galt
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Low
Report
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
3/20
08:25 pm
galt
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point [Seeking Alpha]
High
Report
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point [Seeking Alpha]
3/18
11:06 pm
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/12
08:17 am
galt
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development [Yahoo! Finance]
Low
Report
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development [Yahoo! Finance]
3/12
08:00 am
galt
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Low
Report
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
3/6
06:14 am
galt
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester [Yahoo! Finance]
Low
Report
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester [Yahoo! Finance]
2/21
07:20 am
galt
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21% [Yahoo! Finance]
Low
Report
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21% [Yahoo! Finance]